Study on the Effectiveness of Combination Therapy of Aleximumab and Ivabradine in Postoperative PCI of STEMI Patients
10.13241/j.cnki.pmb.2025.13.009
- VernacularTitle:阿利西尤单抗联合伊伐布雷定对STEMI患者PCI术后有效性研究
- Author:
Chun-meng WU
1
;
Zhi LI
1
;
Shan-shan XU
1
;
Dong-meng WANG
1
;
Cong WANG
1
Author Information
1. 佳木斯市中心医院心内二科 黑龙江佳木斯 154002
- Publication Type:Journal Article
- Keywords:
Aliximumab;
Ivar Bredin;
Acute ST segment elevation myocardial infarction;
PCI;
Ventricular remodeling;
Carotid plaque
- From:
Progress in Modern Biomedicine
2025;25(13):2160-2166
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the application effect of aleximumab combined with ivabradine in patients with STEMI after PCI.Methods:A retrospective analysis was conducted on 90 STEMI patients admitted to Jiamusi Central Hospital for PCI treatment from October 2023 to October 2024.The patients were divided into two groups based on whether they were treated with aleximumab in the early stages of admission.The 45 patients treated with aleximumab combined with ivabradine were assigned to the experimental group,and the 45 patients treated with ivabradine were assigned to the matched group.Compare two groups of blood lipid metabolism indicators[Low density lipoprotein cholesterol(LDL-C),triglycerides,total cholesterol],inflammatory factors[interleukin-6(IL-6),matrix metalloproteinase-9(MMP-9),hypersensitive C-reactive protein(Hs CRP)],ventricular remodeling[Left ventricular mass index(LVMI),end diastolic interventricular thickness(LVST)],and carotid plaques[plaque score,plaque area,carotid intima-media thickness(CarST)].otid intima-media thickness(IMT)was observed,and patients were followed up by telephone and outpatient follow-up for 6 months to record the incidence of cardiovascular adverse events(MACE).Results:Post-treatment,the level of lipid metabolism in both groups was lower than that pretherapy,and the level of lipid metabolism in the test group was lower than that in the matched group(P＜0.05);Post-treatment,the levels of inflammatory factors in both groups were lower than that pretherapy,and the test group was lower than that in the matched group(P＜0.05);Post-treatment,t-test showed that LVMI LVST,The plaque score,plaque area,and TMT level were all lower than pretherapy,and the experimental group was lower than the matched group(P＜0.05);All patients were followed up for 6 months after surgery.Through follow-up,it was found that the total incidence of MACE in the experimental group was 8.89％,while that in the matched group was 26.67％.According to the chi square test,the total incidence of MACE in the experimental group was lower than that in the matched group(P＜0.05).Conclusion:The combination of aleximumab and ivabradine treatment after PCI in STEMI patients can further improve the patient's lipid metabolism,reduce the body's inflammatory response,reverse some carotid plaques,improve ventricular remodeling,and thus further reduce the risk of long-term cardiovascular adverse events in patients.
